Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

A one seven - >>M2M is phase 2

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ombowstring Member Profile
 
Followed By 19
Posts 4,303
Boards Moderated 0
Alias Born 09/27/05
160x600 placeholder
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/10/2021 7:00:00 AM
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
CytoDyn’s leronlimab reduces mortality by 82% at 14 days in critically ill COVID-19 patients Seeking Alpha - 3/30/2021 7:08:56 AM
Philippines OKs use of CytoDyn's leronlimab in COVID-19 Seeking Alpha - 3/29/2021 6:30:52 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/18/2021 7:46:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 8:31:13 AM
CytoDyn promotes from within for COO role Seeking Alpha - 3/16/2021 6:03:45 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, The Next Short Squeeze InvestorsHub NewsWire - 3/11/2021 7:53:20 AM
Enrollment underway in CytoDyn’s long-haulers COVID-19 trial Seeking Alpha - 3/11/2021 5:49:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 5:28:38 PM
CytoDyn to release CD12 trial data on March 8 Seeking Alpha - 3/8/2021 6:34:51 AM
CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada Seeking Alpha - 3/7/2021 11:56:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
ombowstring   Saturday, 07/11/20 08:55:00 AM
Re: Amatuer17 post# 92993
Post # of 164911 
A one seven - >>M2M is phase 2 so FDA may ask for phase 3 as he does not think FDA will consider it unmet need.<< I know that Nader said that, but I think he was just being cautious.

If the clinical trial results meet the primary endpoint, the national media will be all over the story. Fox News and Fox Business News have already brought leronlimab to the public's attention as well as have other media outlets. The presssure on the FDA to approve leronlimab will be intense.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences